Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a BetZacks Investment Research • 05/29/24
Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 05/29/24
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerBusiness Wire • 05/22/24
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to TradeZacks Investment Research • 05/13/24
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingBusiness Wire • 05/06/24
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceBusiness Wire • 04/22/24
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024Business Wire • 04/16/24
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesBusiness Wire • 02/27/24
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceBusiness Wire • 02/21/24
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024Business Wire • 02/08/24
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics PlatformBusiness Wire • 01/08/24